Tysabri (natalizumab) Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

Tysabri (natalizumab) is a monoclonal antibody used to treat relapsing multiple sclerosis (MS) and Crohn's disease by reducing inflammation and protecting nerves from damage. It helps decrease the frequency of relapses and slows the progression of physical disability in adults with relapsing forms of MS, including relapsing-remitting MS (RRMS) and active secondary progressive MS (SPMS).

The primary indications for Tysabri (natalizumab) are multiple sclerosis and Crohn's disease. Multiple sclerosis is a condition that causes the deterioration of the protective covering of nerves. Tysabri is used in various patient settings, including inpatient and outpatient care, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have influenced the tysabri market by increasing costs for monoclonal antibody production inputs, infusion supplies, and cold chain transportation. These cost pressures are most evident in hospital and outpatient infusion centers. North america and europe experience reimbursement sensitivity due to reliance on imported biologics. However, tariffs are encouraging regional biologic manufacturing investments. This is strengthening long-term supply stability and patient access.

The tysabri (natalizumab) market research report is one of a series of new reports from The Business Research Company that provides tysabri (natalizumab) market statistics, including tysabri (natalizumab) industry global market size, regional shares, competitors with a tysabri (natalizumab) market share, detailed tysabri (natalizumab) market segments, market trends and opportunities, and any further data you may need to thrive in the tysabri (natalizumab) industry. This tysabri (natalizumab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tysabri (natalizumab) market size has grown strongly in recent years. It will grow from $2.66 million in 2025 to $2.87 million in 2026 at a compound annual growth rate (CAGR) of 8.1%. The growth in the historic period can be attributed to increasing multiple sclerosis prevalence, approval of natalizumab therapy, neurologist adoption, unmet need in aggressive ms, infusion center expansion.

The tysabri (natalizumab) market size is expected to see strong growth in the next few years. It will grow to $3.87 million in 2030 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to growth in ms diagnosis rates, improved infusion infrastructure, enhanced risk mitigation programs, rising specialty neurology services, long-term clinical outcome support. Major trends in the forecast period include growing use of monoclonal antibodies in ms, preference for high efficacy disease modifying therapies, expansion of outpatient infusion care, improved safety and risk monitoring protocols, rising focus on progressive ms management.

The increasing prevalence of autoimmune disorders is expected to drive the growth of the Tysabri (natalizumab) market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's own cells, tissues, or organs, causing inflammation and damage. These conditions can lead to chronic illnesses such as rheumatoid arthritis or multiple sclerosis, with causes involving a combination of genetic and environmental factors. The rise in autoimmune disorders is attributed to genetic predisposition, environmental triggers, and improved awareness and diagnosis, resulting in more cases being identified. Tysabri is effective for autoimmune disorders as it targets specific immune cells, preventing them from causing inflammation and tissue damage, helping manage conditions like multiple sclerosis and Crohn's disease. For example, in February 2024, Arthritis Australia, a charitable organization advocating for people with arthritis and musculoskeletal conditions, reported that by 2025, around 562,378 Australians are expected to live with rheumatoid arthritis (RA), representing 14% of the total arthritis population. Consequently, the rising prevalence of autoimmune disorders is fueling growth in the Tysabri (natalizumab) market.

The growing focus on personalized medicine is also expected to propel the Tysabri (natalizumab) market forward. Personalized medicine tailors treatments and healthcare strategies to the individual characteristics of each patient, including their genetic profile, environment, and lifestyle, to achieve more effective and precise outcomes. The rise of personalized medicine is driven by advancements in genomic technologies, greater understanding of molecular biology, wider availability of precision diagnostic tools, and demand for targeted therapies that improve patient outcomes while reducing side effects. Tysabri exemplifies personalized medicine by providing a targeted treatment approach for relapsing forms of multiple sclerosis, specifically for patients with certain disease activity and risk profiles, maximizing efficacy while minimizing potential adverse effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022, including seven drugs tailored for cancer and three for other diseases and conditions. Therefore, the rise of personalized medicine is driving growth in the Tysabri (natalizumab) market.

Key players in the Tysabri (natalizumab) market are focusing on expanding treatment options with alternatives such as biosimilars to provide patients with more effective therapies that enhance quality of life and disease management. Biosimilars to Tysabri offer a cost-effective option for treating highly active relapsing-remitting multiple sclerosis, improving access to essential treatments, especially in underserved areas. For instance, in January 2024, Sandoz Group AG, a Switzerland-based pharmaceutical company, launched Tyruko (natalizumab), the first and only biosimilar to Tysabri, for adults with highly active relapsing-remitting multiple sclerosis (RRMS). This launch strengthens Sandoz's biosimilar portfolio and aims to increase access to effective and affordable treatments for people living with multiple sclerosis.

Major companies operating in the tysabri (natalizumab) market are Biogen Idec Inc., Sandoz International GmbH, Polpharma Biologics

North America was the largest region in the tysabri (natalizumab) market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tysabri (natalizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the tysabri (natalizumab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The tysabri market consists of sales of monoclonal antibody therapies, infusion treatments, and immunomodulatory solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tysabri (natalizumab) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses tysabri (natalizumab) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tysabri (natalizumab) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tysabri (natalizumab) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Clinical Indication: Multiple Sclerosis; Crohn's Disease
• 2) By Patient Setting: Inpatient; Outpatient
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Biogen Idec Inc.; Sandoz International GmbH; Polpharma Biologics
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.